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Urinary excretion of nonesterified (NEC) and total cholesterol (TC) has been 
determined in 137 healthy individuals with a range (2 SD) of 0.26-2.2 mg124 
hours NEC and 0.3-3.0 mg/24 hours TC. 264 patients with various internal 
diseases revealed normal values of NEC and TC; neoplasias, diseases of the 
kidney and prostatic adenoma with residual urine had been excluded with 
reasonable certainty. There was no correlation between urinary cholesterol 
excretion and cholesterol plasma levels. In papilloma of the bladder (n = 16) 
NEC hyperexcretion was present in 56%; elevated levels of TC were determined 
in 68%. In carcinoma of the bladder, TINoMo-T2NoMo (n = 28), hyperexcretion 
of NEC occurred in 50% and of TC in 64%. In advanced clinical stages of the 
disease, T3NOMO-T4N4Mld (n = 21), elevated values of NEC were detected in 
76% and of TC in 90%. Since all macroscopically blood contaminated urinary 
samples had been excluded, a determination of total urinary cholesterol 
excretion may be valuable in the diagnosis of papilloma or carcinoma of the 
bladder in the absence of macrohematuria. Occult blood in urine was present 
in 33 of the 65 patients with papilloma or carcinoma of the bladder, which 
was associated in 26 cases with elevated urinary total cholesterol. 32 patients 
revealed a negative test for occult blood in urine. In 22 of these, hyperexcretion 
of urinary total cholesterol was observed, indicating diagnostic sensitivity of 
this parameter for papilloma and carcinoma of the bladder even in the absence 
of microhematuria. However, one has to regard that elevated urinary choles- 
terol levels could also occur in other carcinomas of the urogenital system, 
prostatic adenoma with residual urine and kidney diseases. 
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YPEREXCRETION OF URINARY CHOLES- H TEROL in cancer has been first reported 
by Bloch and Sobotka in 1939 and confirmed 
tion of this parameter seems to be of diag- 
nostic value in the detection of carcinomas 
of the urogenital system, although elevated 
levels could occur in kidney diseases and pros- 
tatic adenoma with residual urine too.3,13,15*17921 
However, there are only a few reports 
about urinary cholesterol excretion in papil- 
loma and carcinoma of the bladder. Only 
the study Frick and Spiteller has demon- 
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strated marked hyperexcretion of urinary cho- 
lesterol in four patients with carcinoma of the 
bladder in advanced clinical  stage^.'^,^^ There- 
fore it was necessary to study urinary choles- 
terol excretion, especially in regard to early 
clinical stages of carcinoma of the bladder 
and precancerous lesions as papilloma. A 
comparative evaluation of nonesterified and 
total urinary cholesterol was undertaken to 
investigate which parameter would be of 
higher diagnostic sensitivity for these diseases. 
MATERIALS A N D  METHODS 
Nonesterified and total urinary cholesterol 
were analyzed in 2 ml aliquots of 24 hours 
urine with a gas-liquid chromatographic assay 
using 4-androstendione as internal standard 
and peakheight ratio technique for quantita- 
tion. This method has been described in 
detail previou~ly.’~ 
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Clinical Material 
Normal range for NEC and TC excretion 
was calculated using standard procedures and 
obtained from a group of clinically healthy 
and biochemically normal individuals. The 
264 patients with various internal diseases 
consisted of 75 with endocrine and metabolic, 
68 with cardiovascular, 78 with gastrointestinal, 
27 with respiratory and 16 with hemopoetic 
disorders. The presence of neoplasias, kidney 
diseases and prostatic adenoma with residual 
urine had been excluded in this second con- 
trol group with reasonable certainty. 
In all patients with papilloma or carcinoma 
of the bladder diagnosis was proven histo- 
pathologically after resection. Only urinary 
samples without macroscopically blood con- 
tamination were included in this study. When 
urinary cholesterol determinations were per- 
formed, patients did not receive any treat- 
FIG. 2. Urinary excretion of 
total cholesterol in normal indi- 
viduals. 
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ment. A diagnosis had been established in 
most cases at the time of the investigation. 
Patients with carcinoma of the bladder were 
classified according to the T N M  system. For 
assessment of T categories, clinical examina- 
tion, urography, cystoscopy, bimanual exami- 
nation under full anesthesia and biopsy or 
transurethral resection of the tumor prior to 
definitive treatment were performed. Classifi- 
cation of N categories based on clinical 
examination, lymphography and urography 
and of M categories on clinical examination, 
chest x-ray and biochemical tests, in more 
advanced primary tumors radiographic or 
isotope studies had been done. Accordingly, 
we  divided patients with carcinoma of the 
bladder in two groups; TINoMo-TzNoMo and 
T3NOMO-T4NQMld. Patients with TI-TS carci- 
noma of the bladder and node involvement 
or metastasis were not present in this study. 
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FIG. 3. Correlation of urinary 
nonesterified and total cholesterol 
in patients with various internal 
diseases without evidence of neo- 
plasia or kidney disorders. 
TOTAL UAINARV CHOLESTEROL MG I Z L  H R  
RESULTS 
Normals 
This group comprised 137 clinically healthy, 
asymptomatic and biochemically normal in- 
dividuals, 67 males and 70 females, covering 
an age range of 14 to 76 years. 
The excretion values for NEC are shown in 
Fig. 1 and those for TC in Fig. 2. Based on 
the statistical analysis of the results, w e  ob- 
tained a mean excretion of 0.76 mg/24 hours 
NEC and 0.92 mg/24 hours TC in males and 
0.84 mg/24 hours NEC and 0.98 mg/24 
hours T C  in females. 
The range for normal values was calculated 
as the mean 2 2 SD including 95% of the 
population. On the basis of these results, an 
upper normal limit of 2.2 mg/24 hours of 
NEC and 2.9 mg/24 hours of TC was deter- 
mined in males and 2.3 mg/24 hours of NEC 
and 3.1 mg/24 hours of TC in females. It is 
important to note that values of urinary 
cholesterol excretion were independent of age 
and presented a log normal distribution. For 
practical purposes, we  defined hyperexcretion 
of NEC as any result exceeding 2.2 mg124 
hours and hyperexcretion of TC any result 
exceeding 3.0 mg/24 hours, since there were 
only minimal differences of urinary choles- 
terol excretion between the male and female 
group. 
In 264 patients with various internal dis- 
eases, urinary excretion of NEC and T C  were 
within the normal range, except 3 cases with 
FIG. 4. Correlation of urinary 
total cholesterol and plasma total 
cholesterol in patients with vari- 
ous internal diseases without evi- 
dence of neoplasia or kidney dis- 
orders. 
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FIG. 5. Comparative evaluation 
of nonesterified and total urinary 
cholesterol in papilloma (0) and 
carcinoma (0) of the bladder, 
TINoMo-T2NoMo. 
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slightly elevated levels of NEC and one pa- 
tient with elevated TC (Fig. 3). There was not 
a constant ratio between NEC and TC; in most 
cases nonesterified cholesterol was the major 
component of total urinary cholesterol. N o  
correlation between urinary cholesterol excre- 
tion and cholesterol plasma levels was ob- 
tained; even in patients with marked hyper- 
cholesterolemia urinary cholesterol values 
were normal (Fig. 4). In papilloma of the 
bladder (n = 16) NEC hyperexcretion was 
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FIG. 6. Comparative evaluation of nonesterified and 
total urinary cholesterol in carcinoma of the bladder, 
T~NoMo-TINIMI.~ .  
present in 56%) elevated levels of T C  were 
determined in 68% (Fig. 5). In carcinoma of 
the bladder, T,NoMo-T2NoMo (n = 28), hy- 
perexcretion of NEC occurred in 50% and of 
T C  in 64% (Fig. 5). 
In advanced clinical stages of the disease, 
T3NoMo-T4N4Mld (n = 21), elevated levels of 
NEC were detected in 76% and of TC in 90% 
(Fig. 6). Urinary cholesterol excretion values 
did not correlate with histological findings. 
NEC-TC ratios varied considerably; in most 
patients with hyperexcretion, cholesterol 
esters were the major component of total 
urinary cholesterol. In 33 of the 65 patients 
with papilloma or carcinoma of the bladder, 
occult blood in urine was present, which was 
associated in 26 cases with elevated urinary 
total cholesterol levels. 32 patients had nega- 
tive test results for occult blood in urine; 
in 22 of these hyperexcretion of urinary 
cholesterol was observed. 
D I s c u s s I o N 
Elevated levels of urinary cholesterol in 
cancer had been determined by Bloch and 
Sobotka and confirmed in later s t ~ d i e s . ~ * ~ * " * ~ ~ *  
l*~lQ Although the scientific value of these 
findings was limited due to the nonspecific 
analytical techniques using colorimetric meth- 
ods, elevated nonesterified urinary cholesterol 
(NEC) had been demonstrated recently by 
Acevedo in patients with carcinomas of steroid 
hormone-producing glands and their main 
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target tissues with specific gas-liquid chroma- 
t ~ g r a p h y . ~ , ~ , ' , ~ * ~  In a previous publication we 
stated that determination of nonesterified or 
total urinary cholesterol may be of value in 
the diagnosis of prostatic cancer, since elevated 
levels of both could be demonstrated even in 
early clinical stages of this disease.15 T o  date 
only few studies exist about urinary choles- 
terol excretion in malignant diseases of the 
bladder. Frick and Spiteller demonstrated 
slightly elevated urinary cholesterol values in 
three cases of papilloma and in four patients 
with carcinoma of the bladder using specific 
massspectrographic analysis. A marked hyper- 
excretion of urinary cholesterol, exceeding 10 
mg/l. was observed in four cases with ad- 
vanced clinical  stage^.'^.*^ 
Our results demonstrated pathologic values 
in papilloma of the bladder of NEC in 56% 
and of TC in 68%. In early clinical stages of 
carcinoma of the bladder, hyperexcretion of 
NEC was present in 50% and in 64% of TC. 
The percentage of elevated values increased 
to 76 of NEC and 90 of T C  in advanced clinical 
stages, corresponding to the observations of 
Frick and Spiteller. Only in 2 patients of this 
group (n = 21) was urinary excretion of total 
cholesterol normal. Diagnostic sensitivity of 
TC determination for the detection of papil- 
lomas or carcinomas of the bladder was con- 
siderably higher in comparison to determina- 
tion of NEC. Combination of both assays did 
not increase the possible detection rate for 
these diseases, since in most cases with hyper- 
excretion, cholesterol esters were the major 
component of urinary total cholesterol. 
Discussing the clinical value of these find- 
ings, one has to consider that early diagnosis 
of carcinoma of the bladder is difficult because 
macrohematuria is an inconsistent symptom. 
Since macroscopically blood contaminated 
urinary specimens had not been included in 
this study, a special determination of urinary 
total cholesterol could be valuable in the diag- 
nosis of asymptomatic carcinoma of the blad- 
der. Additionally, papillomas of the bladder 
could be detected in a considerable percentage 
of patients, which is of interest due to their 
potential malignancy. Occult blood in urine 
was present in 33 of the 65 patients with 
papilloma or carcinoma of the bladder, which 
was associated in 26 cases with elevated urinary 
total cholesterol values. 32 patients revealed 
a negative test for occult blood in urine. In 
22 of these patients, hyperexcretion of TC 
was observed, indicating diagnostic sensitivity 
of this parameter in papilloma and carcinoma 
of the bladder even in the absence of micro- 
hematuria. 
Other common conditions of urinary cho- 
lesterol hyperexcretion are neoplasias of the 
steroid hormone-producing glands and their 
main target tissues, prostatic adenoma with 
residual urine and kidney diseases, especially 
the nephrotic ~ y n d r o m e . ~ * ' ~ * ' ~ . ~ '  These had 
been excluded with reasonable certainty in the 
264 patients with various internal disorders; 
except for 1 patient, all revealed normal 
values of urinary total cholesterol. These 
results demonstrate the real practical value 
of our cutoff limit-3.0 mg/24 hours for TC 
-which is based on the statistical analysis of 
TC levels in the normal group. 
The physiologic mechanisms of urinary 
cholesterol excretion are not known. Acevedo 
et al. suggested an excretion as a protein-bound 
complex on the basis of ultrafiltration studies.' 
Enhanced production of glomerular filtrable 
lipoproteins by the malignant cells are being 
discussed regarding the possibility of their 
causing hyperexcretion of urinary cholesterol 
in cancer of steroid hormone-producing 
glands or their main target tissues. In the 
case of papilloma or carcinoma of the bladder, 
we suggest that urothelial lesions may be 
responsible for the observed elevated urinary 
cholesterol values, similar in nature to the 
finding of increased urinary cholesterol in 
patients with prostatic adenoma in advanced 
clinical stages with residual urine. 
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